Immatics biotechnologies
VerifiedCombines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets.
Launch date
Employees
Market cap
-
Net debt
-
Enterprise valuation
$712m (Public information from Jul 2024)
Share price
$12.39 IMTX
Company register number HRB 382151 (Stuttgart)
Tübingen Baden-Württemberg (HQ)
Deals in current and previous year:
| EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 69 % | 11 % | 397 % | (69 %) | 8 % | (2 %) | (14 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (206 %) | (217 %) | 27 % | (149 %) | (184 %) | (255 %) | (458 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (733 %) | (268 %) | 22 % | (180 %) | (217 %) | (234 %) | (344 %) |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 215 % | 252 % | 62 % | 220 % | - | - | - |
Source: Dealroom estimates
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor investor investor investor investor investor investor investor | $0.0 | round |
| investor investor investor investor investor investor | $0.0 | round | |
| investor | $0.0 | round | |
| investor | $0.0 Valuation: $0.0 14.2x EV/LTM Revenues -9.2x EV/LTM EBITDA | round | |
| investor investor investor investor investor investor investor investor | $0.0 Valuation: $0.0 14.2x EV/LTM Revenues -9.2x EV/LTM EBITDA | round | |
| investor investor investor investor investor investor investor investor investor investor investor investor | $0.0 | round | |
* | $35.0m | Private Placement VC | |
| Total Funding | 000k | ||
Related Content
Recent News about Immatics biotechnologies
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Immatics biotechnologies
Edit
exited